More on HROW
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $36.17 |
|
|||
| Open | $35.24 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $37.34 | ||||
| Day Low | $34.72 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,338,440 | ||||
- Form 4 HARROW, INC. For: Mar 03 Filed by: Opaleye Management Inc.
- Harrow Health (HROW) PT Lowered to $60 at Lake Street
- Harrow Health (HROW) PT Lowered to $91 at Cantor Fitzgerald
- Harrow Health (HROW) PT Lowered to $62 at Ladenburg Thalmann
- Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
- Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright
- Form 4 HARROW, INC. For: Feb 27 Filed by: Opaleye Management Inc.
- William Blair Reiterates Outperform Rating on Harrow Health (HROW): "We believe the long-term growth outlook is attractive"
- Harrow begins phase 3 trial for TRIESENCE in cataract surgery patients
- Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
Entities mentioned with HROW
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- B. Riley | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- S3 | View Related Stories »
- Show More...
